More MS news articles for August 2000

Update On Product Pipeline For Jacobson Resonance Enterprises
 
Monday August 28, 2:18 pm Eastern Time
Press Release
SOURCE: Jacobson Resonance Enterprises, Inc.

BOYNTON BEACH, Fla., Aug. 28 /PRNewswire/ -- Jacobson Resonance Enterprises, Inc. (OTC Bulletin Board: JRSE - news) reviewed today the Company's product pipeline based upon its patented technology generically defined as Jacobson Resonance. The utilization of extremely low level, low frequency magnetic fields promulgates a sharp focus in method and delivery systems which cuts across a great diversity of applications in medicine, agricultural, and environmental industries.
 
In the United States and Europe, Phase III double blind clinical studies with 262 patients have been completed in chronic pain of the knee joint secondary to osteoarthritis. Device applications have been submitted to the Food and Drug Administration as well as regulatory agencies for the CE marking in the European Community. There are more than 20 million Americans and 45 million Europeans who suffer from osteoarthritis. In 1999, the FDA determined that the use of the Jacobson Resonator for treatment of osteoarthritis of the knee joint entails Non-Significant Risk, and the Company now awaits regulatory approval of its successful clinical trials and is preparing for the commercialization process.
 
Jacobson Resonance of Spain (the Company's licensee in Europe, the Middle East, and Africa) has successfully guided its resonators through CETECOM homologation tests (being technical standards certified by the European Union), has closely complied with Direccion de Productos Sanitarios y Farmaceuticos (the Spanish Health Ministry), and has satisfied the European Union's Medical Device Directive, with its resonators having been judged to be non-hazardous. Final documentation required to obtain CE-Mark approval was submitted in January 2000. J. Resonance of Spain is preparing for regulatory approval and marketing throughout the European Community.
 
Double blind, randomized and placebo-controlled clinical studies in Phase I using FDA/IRB protocols are now ongoing in epilepsy at the University of Oklahoma, Alzheimer's disease at the Baptist Hospital in Jackson, Miss., and fibromyalgia also at a clinical facility in Jackson, Miss. There are 2.5 million people in the USA who suffer from epilepsy and nearly 5.5 million in 23 leading Eastern and Western European nations. Four million in the USA and 8.715 million people in Europe suffer from Alzheimer's disease, a progressive degenerative disorder of the brain that generally takes its toll on patients' life savings. Currently, 7.5 million people in the USA and 16.341 million people in Europe suffer from fibromyalgia, a chronic and extremely painful musculoskeletal disorder affecting ligaments, muscles, and tendons. Range finding, case-controlled clinical studies in the
aforementioned areas have been encouraging, and Jacobson Resonators are anticipated to be proven effective in the treatment and adjunctive management of these maladies.
 
Pre-clinical studies in breast cancer (in vitro) at Mississippi State University, angina (in vivo rat model) at the University of Oklahoma Health Sciences Center, nerve regeneration (in vitro) at the Weill Medical College of Cornell University, neuropathy (in vivo in mice) at Fairleigh Dickinson University, bone and cartilage regeneration (in vitro) at Mississippi State University, and cardiac arrhythmias (in vitro in myocytes and in vivo in dogs) at the University of Oklahoma Health Sciences Center have been performed and point to various possible clinical applications for the Jacobson Resonator which continue to be investigated and developed. Studies are also ongoing in the treatment of horses at the Mississippi State University College of Veterinary Medicine. Bacterial studies (in vitro) are planned at MSU.
 
Various range finding case-controlled clinical studies have been performed under Institutional Review Board approvals in the total chronic pain spectrum both in the USA and Europe, including migraine and cluster headaches, lower back pain, neuropathies, carpal tunnel and tarsal tunnel syndromes, sports injuries such as sprains, spasms, and tendonitis, and wound healing. Additionally, preliminary clinical studies under IRB in the neurological area have included cerebral palsy, muscular dystrophy, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, autism, attention deficit disorders, and depression.
 
Jacobson resonated water absorption studies at the University of Oklahoma have also indicated a potential benefit in that windows of amplitudes and frequencies have shown increased rate of absorption across a semi-permeable membrane (in vitro). In vivo studies in dogs using resonated water are planned at OKU as well as studies in pigs at MSU. The significance of water absorption studies may relate to Texas A & M University studies performed in squash, cucumbers, and radishes. A better understanding of underlying mechanisms involving enhanced growth of plants is sought, and further studies involving seed germination are now planned at Texas A & M and Mississippi State. Various studies have indicated that Jacobson Resonance may enhance the growth of fruits, vegetables, and grass. Examination of seeds in germination studies for possible genetic effects in growth and repair and further analysis of plant rate of uptake of organized water are planned. Additionally, studies at Texas A & M have indicated an influence of picoTesla range magnetic fields on the taste of wine. Thus, this avenue is also open for exploration.
 
Dr. Jerry Jacobson, inventor of Jacobson Resonance technology, Chairman and CEO of JRSE, stated, "I believe that we have made remarkable progress in science and technology within a short period of time given a small amount of financial support. As regulatory approvals come in and commercial benefit is derived of initiatives not requiring regulatory approvals in areas including the resonation of concrete, water, animals, seeds, and some pharmaceutical agents, as well as non-medical portable resonators for home use, increased funding for R&D will drive our science forward to become a leading contribution in the next millennium. I have predicted all along that in the case of JRSE the science will drive the business and so much positive data already gleaned, I believe, must inevitably drive shareholder value to the highest potentials. We must appreciate that rigorous scientific studies take time and dedication to truth, and patience is the highest virtue required for ultimate success and acceptance by academic and regulative authority."
 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance, or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements.
 
SOURCE: Jacobson Resonance Enterprises, Inc.